Showing results (201-210 of 331) with videos related to
Sort By:
Pageof 34
JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.Immunity|November 1, 2025
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitorsMingming Wu, Shiyue Yang, Zhentao Yang, et al.Science Translational Medicine|August 16, 2019
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21Anna E Vilgelm, Nabil Saleh, Rebecca Shattuck-Brandt, et al.Journal for Immunotherapy of Cancer|July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world dataKerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.Cancer Immunology Research|November 11, 2018
Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor TypesAllison R Greenplate, Daniel D McClanahan, Brian K Oberholtzer, et al.Cancer Cell|January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addictionGatien Moriceau, Willy Hugo, Aayoung Hong, et al.American Journal of Hematology|February 22, 2019
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitorsRebecca Karp Leaf, Christopher Ferreri, Deepa Rangachari, et al.Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.JCO Precision Oncology|January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic CancersMatthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.Cell|March 22, 2016
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.Pageof 34